Gilead Sciences Stock News

Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong performance in HIV treatments, with Biktarvy leading and new regimens expected by 2030, and upgraded 2024 guidance for >$28bn revenues, EPS of >$4. Liver disease and oncology divisions have slightly under...

Subscribers to  Chart of the Week  received this commentary on Sunday, December 8.

If GILD stays below 100, the investor can continue selling call options until the shares get called away. The post Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade appeared first on Investor's Business Daily.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the...

Bullish sentiment rules

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined with Gilead's robust HIV portfolio, position the company for significant revenue growth. Despite competition and debt, Gilead's financial health is solid, with substantial cash flow and manageable debt le...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The Breakt...

FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Terray's tNova platform combines high-throughput chemical experimentation and computational analysis with a generative...